Discover and read the best of Twitter Threads about #PancChat
Most recents (5)
1/ 🌟 Calling #Oncology HCPs 🌟
🆕 #TumorBoardTuesday #Tweetorial #GI22
🧬 HER2 in Gastrointestinal Cancer
👥 @MPishvaian @BenWestphalen
Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.
CME ℹ️ bit.ly/3ruGO07
⁉️ Your specialty
🆕 #TumorBoardTuesday #Tweetorial #GI22
🧬 HER2 in Gastrointestinal Cancer
👥 @MPishvaian @BenWestphalen
Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.
CME ℹ️ bit.ly/3ruGO07
⁉️ Your specialty
2/ 🗒️ Full reference list & glossary 👉 bit.ly/3tBrmC7
🔑 Key #CME & faculty info 👇, full info 👉 bit.ly/3ruGO07
#TumorBoardTuesday #GI22
🔑 Key #CME & faculty info 👇, full info 👉 bit.ly/3ruGO07
#TumorBoardTuesday #GI22
3/ 🛑 POLL 🛑
🤔 How frequently do you currently employ emerging novel therapies & clinical trial enrollment for your patients ❓
#TumorBoardTuesday #GI22
🤔 How frequently do you currently employ emerging novel therapies & clinical trial enrollment for your patients ❓
#TumorBoardTuesday #GI22
1/ 🌟 Calling #Oncology HCPs 🌟
🆕 #TumorBoardTuesday #Tweetorial
🚨 🧬 HER2 in Breast Cancer
👥 @MPishvaian & @ErikaHamilton9
Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.
CME ℹ️ bit.ly/3ecVOcC
🗣️ What's your specialty ⁉️
🆕 #TumorBoardTuesday #Tweetorial
🚨 🧬 HER2 in Breast Cancer
👥 @MPishvaian & @ErikaHamilton9
Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.
CME ℹ️ bit.ly/3ecVOcC
🗣️ What's your specialty ⁉️
2/ 🗒️ Full reference list & glossary 👉 bit.ly/3yMvIGW
🔑 Key #CME & faculty info 👇, full info 👉 bit.ly/3ecVOcC
#TumorBoardTuesday
🔑 Key #CME & faculty info 👇, full info 👉 bit.ly/3ecVOcC
#TumorBoardTuesday
3/ 🛑 POLL 🛑
🤔 In a Ph3 trial, which agent has demonstrated an ORR of nearly 80% ❓
#TumorBoardTuesday
🤔 In a Ph3 trial, which agent has demonstrated an ORR of nearly 80% ❓
#TumorBoardTuesday
1/12 #TumorBoardTuesday
Thurs 10/12/21 Case🎀
@ShaalanBeg @CancerCommons present a case of #PancreaticCancer that challenges us to🤔about cell signaling & mol bio➡️better outcomes.
📚We captured as much of the chat as we could:
twitter.com/i/events/14479…
#PanCan #KRAS #OncTwitter
Thurs 10/12/21 Case🎀
@ShaalanBeg @CancerCommons present a case of #PancreaticCancer that challenges us to🤔about cell signaling & mol bio➡️better outcomes.
📚We captured as much of the chat as we could:
twitter.com/i/events/14479…
#PanCan #KRAS #OncTwitter
2/12 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages:
We discussed #PancreaticCancer & specific #KRAS mut
✅All KRAS muts aren’t ≠
✅KRAS G12R➡️⬆️autophagy
✅Autophagy= tumor can♻️cell components ➡️resistance
✅MEKi + autophagy inhib= strat for G12R
✅Repeat NGS on prog is🗝️!
Thurs Case🎀
Take🏠messages:
We discussed #PancreaticCancer & specific #KRAS mut
✅All KRAS muts aren’t ≠
✅KRAS G12R➡️⬆️autophagy
✅Autophagy= tumor can♻️cell components ➡️resistance
✅MEKi + autophagy inhib= strat for G12R
✅Repeat NGS on prog is🗝️!
3/12
#TumorBoardTuesday
Thursday Case🎀
👉👉 Don’t forget to pick up 🆓 #CME credit by answering 3 quick ❓
Here is the post-test 🔗: bit.ly/3Bzgply
ALL CME 🔗: integrityce.com/tbt
#TumorBoardTuesday
Thursday Case🎀
👉👉 Don’t forget to pick up 🆓 #CME credit by answering 3 quick ❓
Here is the post-test 🔗: bit.ly/3Bzgply
ALL CME 🔗: integrityce.com/tbt
#PancChat #TumorBoardTuesday
💥A truly unique TBT w/ a hybrid🗣️on BRCA-mut Panc Ca with @letswinpc @drallysonocean & @TumorBoardTues
➡️Here is this week's Thursday Case🎀
👉👉And pick up your🆓#CME credit by answering 2 quick❓
Here is the post-test🔗
surveymonkey.com/r/GBYGYB2
💥A truly unique TBT w/ a hybrid🗣️on BRCA-mut Panc Ca with @letswinpc @drallysonocean & @TumorBoardTues
➡️Here is this week's Thursday Case🎀
👉👉And pick up your🆓#CME credit by answering 2 quick❓
Here is the post-test🔗
surveymonkey.com/r/GBYGYB2
#PancChat #TumorBoardTuesday
Thursday Case🎀
(Case from 04/20/21)
We🗣️a lot about #PancreaticCancer including:
✅Delays to Dx
✅Choosing NOT to have chemo
✅Universal🧬testing
✅BRCA mut & PARP inh
We captured as much as we could in these two moments:
twitter.com/i/events/13838…
Thursday Case🎀
(Case from 04/20/21)
We🗣️a lot about #PancreaticCancer including:
✅Delays to Dx
✅Choosing NOT to have chemo
✅Universal🧬testing
✅BRCA mut & PARP inh
We captured as much as we could in these two moments:
twitter.com/i/events/13838…
#PancChat #TumorBoardTuesday
Thursday Case🎀
(Case from 04/20/21)
And this moment too:
twitter.com/i/events/13838…
Thursday Case🎀
(Case from 04/20/21)
And this moment too:
twitter.com/i/events/13838…
#TumorBoardTuesday
🙏for joining &⚖️in on a robust🗣️ with A LOT of deep🔬on NRG-1 fusion+ #CRC led by @benweinbergmd
➡️Here is this week's Thursday Case🎀
👉👉Don't forget to pick up your🆓#CME credit by answering 2 quick❓
Here is the post-test🔗
bit.ly/3fFpTUe
🙏for joining &⚖️in on a robust🗣️ with A LOT of deep🔬on NRG-1 fusion+ #CRC led by @benweinbergmd
➡️Here is this week's Thursday Case🎀
👉👉Don't forget to pick up your🆓#CME credit by answering 2 quick❓
Here is the post-test🔗
bit.ly/3fFpTUe
#TumorBoardTuesday
Thursday Case🎀
(Case from 04/06/21)
We discussed #colorectalcancer and:
✅ChemoTx choices and sequencing
✅5FU cardiotox
✅KRAS and other🧬alterations
✅And of course all about NRG-1
We captured as much as we could in this moment:
twitter.com/i/events/13794…
Thursday Case🎀
(Case from 04/06/21)
We discussed #colorectalcancer and:
✅ChemoTx choices and sequencing
✅5FU cardiotox
✅KRAS and other🧬alterations
✅And of course all about NRG-1
We captured as much as we could in this moment:
twitter.com/i/events/13794…
#TumorBoardTuesday
Thursday Case🎀
(Case from 04/06/21)
@benweinbergmd presented a case of a patient with met #CRC
👍2-dary🗣️on:
➡️What chemo after metastasectomy
➡️💪evidence for FOLFOXIRI+mAb for metCRC
ncbi.nlm.nih.gov/pubmed/17470860
ncbi.nlm.nih.gov/pubmed/16508637
ncbi.nlm.nih.gov/pubmed/26338525
Thursday Case🎀
(Case from 04/06/21)
@benweinbergmd presented a case of a patient with met #CRC
👍2-dary🗣️on:
➡️What chemo after metastasectomy
➡️💪evidence for FOLFOXIRI+mAb for metCRC
ncbi.nlm.nih.gov/pubmed/17470860
ncbi.nlm.nih.gov/pubmed/16508637
ncbi.nlm.nih.gov/pubmed/26338525
